Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
Prostate Cancer
DRUG: Degarelix 240/80 mg
Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196, Day 28 to Day 196
Proportion of Patients With Testosterone Level ≤0.5 ng/mL at Day 3, At day 3|Percentage Change in Prostate-specific Antigen (PSA) From Baseline to Day 28, To Day 28|Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL)From Day 56 to Day 196, Day 56 to Day 196|Cumulative Probability of no PSA Failure From Day 28 to Day 196, PSA failure was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir., To Day 196|Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables, The figures present the number of participants who had markedly abnormal levels of safety laboratory variables. Only the laboratory variables that had at least one percentage of participants in either group with abnormal value are presented, more variables were included in the study., To Day 196|Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight, This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value., To Day 196
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.